Pharmaceuticals
The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer.
1. A compound of formula (I)
or a tautomer thereof, wherein:
(a) Y is a direct bond, and R 3 is selected from aryl, and —(C 1 -C 4 )alkylene-O—(C 1 -C 4 )alkyl; or
(b) Y is (C 1 -C 4 )alkylene, and R 3 is selected from aryl, (C 3 -C 7 )cycloalkyl and a 3 to 10-membered heterocyclyl;
Z is an oxygen or is absent;
R 1 is selected from H, halo, OH, CN, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —NHSO 2 R 6 , —NR 6 R 7 , —C(O)R 6 , —CO 2 R 6 , —C(O)NR 6 R 7 , —C(O)NR 6 SO 2 R 8 , aryl and 3 to 10-membered heterocyclyl;
R 2 is selected from H, halo, OH, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —NR 6 R 7 , —CO 2 R 6 , —C(O)NR 6 R 7 , —C(O)NR 6 SO 2 R 8 , and 3 to 10-membered heterocyclyl; or
R 1 and R 2 may be joined to form a (C 2 -C 5 )alkylene link, said link optionally incorporating 1 or 2 heteroatoms each independently selected from N, O and S;
R 5 is absent and R 4 is selected from H, (C 3 -C 7 )cycloalkyl, aryl, —(CH 2 )aryl, —C(O)R 9 , —CO 2 R 9 , —(C 1 -C 6 )alkylene-O—C(O)R 9 , —(C 1 -C 6 )alkylene-O—CO 2 R 9 ), —C(O)NR 9 R 10 , —(C 1 -C 6 )alkylene-O—C(O)NR 9 R 10 and —(C 1 -C 6 )alkylene-O—P(O)(OH) 2 ; or
R 4 is absent and R 5 is selected from R 9 , —C(O)R 9 , —CO 2 R 9 , —(C 1 -C 6 )alkylene-O—C(O)R 9 , —(C 1 -C 6 )alkylene-O—CO 2 R 9 , —C(O)NR 9 R 10 , —(C 1 -C 6 )alkylene-O—C(O)NR 9 R 10 and —(C 1 -C 6 )alkylene-O—P(O)(OH) 2 ;
R 6 and R 7 are each independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, and —(C 1 -C 6 )alkylene(C 3 -C 7 )cycloalkyl; or R 6 and R 7 taken together with the nitrogen to which they are attached form a 3 to 6 membered saturated heterocycle optionally containing a further one or two heteroatoms selected from N, O and S;
R 8 is selected from (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl and phenyl;
R 9 and R 10 are each independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, aryl, —(CH 2 )aryl and 3 to 10-membered heterocyclyl; or R 9 and R 10 , taken together with the nitrogen to which they are attached, form a 3 to 10-membered heterocyclyl group; and
R 11 and R 12 are independently selected from H and (C 1 -C 6 )alkyl; or R 11 and R 12 together with the N to which they are attached form a 3 to 6 membered saturated heterocyclyl optionally containing a further one or two heteroatoms selected from N, O and S;
wherein said alkyl, cycloalkyl, alkoxy, aryl and heterocyclyl groups being optionally substituted by one or more atoms or groups independently selected from halo, OH, oxo, CF 3 , CN, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkylene-OH, —NR 11 R 12 , —(C 1 -C 6 )alkylene-NR 11 R 12 , aryl and 3 to 10-membered heterocyclyl; or
a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein R 1 is selected from:
(a) H;
(b) CN;
(c) halo
(d) (C 1 -C 6 )alkyl optionally substituted by one to three halo atoms;
(e) tetrahydrofuranoxy;
(f) (C 1 -C 6 )alkyl substituted by a 3 to 6 membered saturated heterocycyl containing 1 to 3 hetero atoms independently selected from N, O and S wherein said heterocyclyl is optionally substituted by one to three groups independently selected from CF 3 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy and —(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl;
(g) —(C 1 -C 4 )alkylene-O—(C 1 -C 6 )alkyl;
(h) —(C 1 -C 4 )alkylene-N(H)—(C 1 -C 4 )alkylene-O—(C 1 -C 4 )alkyl;
(i) (C 1 -C 6 )alkoxy optionally substituted by OH or cyclopropyl;
(j) (C 3 -C 7 )cycloalkyl;
(k) —(C 1 -C 4 )alkylene(C 3 -C 7 )cycloalkyl;
(l) —C(O)NR 6 R 7 ;
(m) —CO 2 R 6 ;
(n) —C(O)R 6 ;
(o) a 5 membered aromatic heterocyclyl comprising (i) 1 to 4 nitrogen atoms, or (ii) 1 to 2 nitrogen atoms and 1 oxygen or sulphur atom, or (iii) 1 oxygen or sulphur atom; or a 6-membered aromatic heterocyclyl comprising 1 to 3 nitrogen atoms, said 5 and 6 membered aromatic heterocyclyl being optionally substituted by one to three atoms or groups independently selected from halo, OH, CF 3 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, —(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkylene-OH , —NR 11 R 12 and —(C 1 -C 6 )alkylene-NR 11 R 12 ;
(p) phenyl optionally substituted by 1 to 3 halo atoms;
(q) —NR 6 R 7 ; and
(r) —NH—(C 1 -C 4 )alkylene-O—(C 1 -C 6 )alkyl; or
a pharmaceutically acceptable salt thereof, wherein R 6 , R 7 , R 11 and R 12 are as defined in claim 1 .
3. A compound according to claim 1 , wherein R 1 is selected from methyl or ethyl substituted by one to three fluoro atoms; cyclopropyl; —(C 1 -C 2 )alkylene-O—(C 1 -C 2 )alkyl; (C 1 -C 4 )alkoxy optionally substituted by OH or cyclopropyl; —COCH 3 ; —CH 2 OCH 3 ; and —CO 2 CH 3 ; or a pharmaceutically acceptable salt thereof.
4. A compound according to claim 1 , wherein R 1 is cyclopropyl or CF 3 , or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 1 , wherein R 1 is a 5 membered aromatic heterocyclyl comprising (i) 1 to 4 nitrogen atoms, or (ii) 1 to 2 nitrogen atoms and 1 oxygen or sulphur atom, or (iii) 1 oxygen or sulphur atom, said 5 membered aromatic heterocyclyl being optionally substituted by one to three atoms or groups independently selected from halo, OH, CF 3 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, —(C 1 -C 3 )alkylene-O—(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkylene-OH, —NR 11 R 12 and —(C 1 -C 3 )alkylene-NR 11 R 12 , or a pharmaceutically acceptable salt thereof, wherein R 11 and R 12 are as defined in claim 1 .
6. A compound according to claim 5 , wherein R 1 is selected from imadazolyl, oxazolyl, oxadiazolyl, triazole, pyrazole and thiazole, all of which are optionally substituted by by one to three atoms or groups independently selected from halo, OH, CF 3 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, —(C 1 -C 3 )alkylene-O—(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkylene-OH and —(C 1 -C 3 )alkylene-NR 11 R 12 , or a pharmaceutically acceptable salt thereof.
7. A compound according to claim 6 , wherein R 1 is selected from unsubstituted oxazolyl, triazole, pyrazole and thiazole, or a pharmaceutically acceptable salt thereof.
8. A compound according to claim 1 , wherein R 2 is selected from:
(a) H;
(b) halo;
(c) (C 1 -C 6 )alkyl optionally substituted by one to three halo atoms;
(d) tetrahydrofuranoxy;
(e) (C 1 -C 6 )alkyl substituted by a 3 to 6 membered saturated heterocycyl containing 1 to 3 hetero atoms independently selected from N, O and S wherein said heterocyclyl is optionally substituted by one to three groups independently selected from CF 3 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy and —(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl;
(f) —(C 1 -C 4 )alkylene-O—(C 1 -C 6 )alkyl;
(g) —(C 1 -C 4 )alkylene-N(H)—(C 1 -C 4 )alkylene-O—(C 1 -C 4 )alkyl;
(h) (C 1 -C 6 )alkoxy optionally substituted by OH or cyclopropyl;
(i) (C 3 -C 7 )cycloalkyl;
(j) —(C 1 -C 4 )alkylene(C 3 -C 7 )cycloalkyl;
(k) —C(O)NR 6 R 7 ;
(l) —CO 2 R 6 ;
(m) —C(O)R 6 ;
(n) a 5 membered aromatic heterocyclyl comprising (i) 1 to 4 nitrogen atoms, or (ii) 1 to 2 nitrogen atoms and 1 oxygen or sulphur atom, or (iii) 1 oxygen or sulphur atom; or a 6-membered aromatic heterocyclyl comprising 1 to 3 nitrogen atoms, said 5 and 6 membered aromatic heterocyclyl being optionally substituted by one to three atoms or groups independently selected from halo, OH, CF 3 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, —(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkylene-OH, —NR 11 R 12 and —(C 1 -C 6 )alkylene-NR 11 R 12 ;
(o) phenyl optionally substituted by 1 to 3 halo atoms;
(p) —NR 6 R 7 ; and
(q) —NH—(C 1 -C 4 )alkylene-O—(C 1 -C 6 )alkyl; or
a pharmaceutically acceptable salt thereof, wherein R 6 , R 7 , R 11 and R 12 are as defined in claim 1 .
9. A compound according to claim 1 , wherein R 2 is H or methyl, or a pharmaceutically acceptable salt thereof.
10. A compound according to claim 1 , wherein R 2 is H, or a pharmaceutically acceptable salt thereof.
11. A compound according to claim 1 , wherein Y is methylene; and R 3 is selected from aryl; a 5 membered aromatic heterocyclyl comprising (i) 1 to 4 nitrogen atoms, or (ii) 1 to 2 nitrogen atoms and 1 oxygen or sulphur atom, or (iii) 1 oxygen or sulphur atom; and a 6-membered aromatic heterocyclyl comprising 1 to 3 nitrogen atoms; said aryl and aromatic heterocycle being optionally substituted by one to three atoms or groups independently selected from halo, OH, oxo, CF 3 , CN, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkylene-OH, —NR 11 R 12 , —(C 1 -C 6 )alkylene-NR 11 R 12 , aryl and 3 to 10-membered heterocyclyl, or a pharmaceutically acceptable salt thereof, wherein R 11 and R 12 are as defined in claim 1 .
12. A compound according to claim 1 , wherein Y is methylene; and R 3 is selected from phenyl, pyridyl, pyrimidyl, pyridizinyl and pyrazinyl, each of which are optionally substituted by one to three atoms or groups independently selected from halo, (C 1-4 )alkyl, (C 1 -C 4 )alkoxy and CF 3 , or a pharmaceutically acceptable salt thereof.
13. A compound according to claim 1 , wherein Y is methylene; and R 3 is selected from phenyl, pyridin-3-yl and 6-methyl-pyridin-3-yl, or a pharmaceutically acceptable salt thereof.
14. A compound according to claim 1 , wherein R 5 is absent; and
R 4 is selected from —(C 1 -C 6 )alkylene-O—C(O)R 9 , —(C 1 -C 6 )alkylene-O—CO 2 R 9 , —(C 1 -C 6 )alkylene-O—C(O)NR 9 R 10 and —(C 1 -C 6 )alkylene-O—P(O)(OH) 2 , or a pharmaceutically acceptable salt thereof, wherein R 9 and R 10 are as defined in claim 1 .
15. A compound according to claim 1 , wherein R 4 is H and R 5 is absent, or a pharmaceutically acceptable salt thereof.
16. A compound according to claim 1 , wherein R 4 is absent; and
R 5 is selected from —(C 1 -C 6 )alkylene-O—C(O)R 9 , —(C 1 -C 6 )alkylene-O—CO 2 R 9 ), —(C 1 -C 6 )alkylene-O—C(O)NR 9 R 10 and —(C 1 -C 6 )alkylene-O—P(O)(OH) 2 , or a pharmaceutically acceptable salt thereof, wherein R 9 and R 10 are as defined in claim 1 .
17. A compound according to claim 1 wherein:
Y is methylene;
R 1 is selected from CF 3 , cyclopropyl, and oxazole;
R 2 is H;
R 3 is selected from phenyl, pyridin-3-yl and 6-methyl-pyridin-3-yl.
R 4 is H; and
R 5 is absent; or
or a pharmaceutically acceptable salt thereof.
18. A compound of formula (Ic)
or a tautomer thereof, wherein:
Y is a methylene;
R 1 and R 2 are each independently selected from H, halo, OH, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —NR 6 R 7 , —CO 2 R 6 , —C(O)NR 6 R 7 , —C(O)NR 6 SO 2 R 8 , aryl and 3 to 10-membered heterocyclyl; or
R 1 and R may be joined to form a (C 2 -C 5 )alkylene link, said link optionally incorporating 1 or 2 heteroatoms each independently selected from N, O and S;
R 3 is selected from (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, aryl and 3 to 10-membered heterocyclyl;
R 4 is selected from R 9 , —C(O)R 9 , —CO 2 R 9 and —C(O)NR 9 R 10 , and R 5 is absent; or
R 5 is selected from R 9 , —C(O)R 9 , —CO 2 R 9 and —C(O)NR 9 R 10 , and R 4 is absent;
R 6 and R 7 are each independently selected from H and (C 1 -C 6 )alkyl;
R 8 is selected from (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl and phenyl; and
R 9 and R 10 are each independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, aryl, —(CH 2 )aryl and 3 to 10-membered heterocyclyl; or
R 9 and R 10 , taken together with the nitrogen to which they are attached, form a 3 to 10-membered heterocyclyl group;
wherein said alkyl, cycloalkyl, alkoxy, aryl and heterocyclyl groups being optionally substitued by one or more groups independently selected from halo, OH, oxo, CF 3 , CN, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, —NH(C 1 -C 6 )alkyl, —N((C 1 -C 6 )alkyl) 2 , aryl and 3 to 10-membered heterocyclyl; or
or a pharmaceutically acceptable salt thereof,
with the proviso that when R 1 and R 2 are H; Z and R5 are absent, then
(a) R 4 is not methyl when Y—R 3 is ethyl; and
(b) R 4 is not H or methyl when Y—R 3 is methyl.
19. A compound according to claim 1 , selected from:
4-Amino-1-benzyl-6-cyclopropyl-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
4-Amino-1-benzyl-6-oxazol-2-yl-1,3-dihydro-imidazo[4,5-c]pyridin-2-one; and
4-Amino-1-benzyl-6-trifluoromethyl-1,3-dihydro-imidazo[4,5-c]pyridine-2-one ; or
a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition, comprising a compound of the formula
or a tautomer thereof, wherein:
(a) Y is a direct bond, and R 3 is selected from aryl, (C 1 -C 6 )alkyl and —(C 1 -C 4 )alkylene-O—(C 1 -C 4 alkyl; or
(b) Y is (C 1 -C 4 )alkylene, and R 3 is selected from aryl, (C 3 -C 7 )cycloalkyl and a 3 to 10-membered heterocyclyl;
Z is an oxygen or is absent;
R 1 is selected from H, halo, OH, CN, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —NHSO 2 R 6 , —NR 6 R 7 , —C(O)R 6 , —CO 2 R 6 , —C(O)NR 6 R 7 , —C(O)NR 6 SO 2 R 8 , aryl and 3 to 10-membered heterocyclyl;
R 2 is selected from H, halo, OH, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —NR 6 R 7 , —CO 2 R 6 , —C(O)NR 6 R 7 , —C(O)NR 6 SO 2 R 6 , and 3 to 10-membered heterocyclyl; or
R 1 and R 2 may be joined to form a (C 2 -C 5 )alkylene link, said link optionally incorporating 1 or 2 heteroatoms each independently selected from N, O and S;
R 5 is absent and R 4 is selected from H, (C 3 -C 7 )cycloalkyl, aryl, —(CH 2 )aryl, —C(O)R 9 , —CO 2 R 9 , —(C 1 -C 6 )alkylene-O—C(O) R 9 , —(C 1 -C 6 )alkylene-O—CO 2 R 9 ), —C(O)NR 9 R 10 , —(C 1 -C 6 )alkylene-O—C(O)NR 9 R 10 and —(C 1 -C 6 )alkylene-O—P(O)(OH) 2 ; or
R 4 absent and R 5 is selected from R 9 , —C(O)R 9 , —CO 2 R 9 , —(C 1 -C 6 )alkylene-O—C(O)R 9 , —(C 1 -C 6 )alkylene-O—CO 2 R 9 , —C(O)NR 9 R 10 , —(C 1 -C 6 )alkylene-O—C(O)NR 9 R 10 and —(C 1 -C 6 )alkylene-O—P(O)(OH) 2 ;
R 6 and R 7 are each independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, and —(C 1 -C 6 )alkylene(C 3 -C 7 )cycloalkyl; or R 6 and R 7 taken together with the nitrogen to which they are attached form a 3 to 6 membered saturated heterocycle optionally containing a further one or two heteroatoms selected from N, O and S;
R 8 is selected from (C 1 -C 6 ), (C 3 -C 7 )cycloalkyl and phenyl;
R 9 and R 10 are each independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, aryl, —(CH 2 )aryl and 3 to 10-membered heterocyclyl; or R 9 and R 10 , taken together with the nitrogen to which they are attached, form a 3 to 10 -membered heterocyclyl group; and
R 11 and R 12 are independently selected from H and (C 1 -C 6 )alkyl; or R 11 and R 12 together with the N to which they are attached form a 3 to 6 membered saturated heterocyclyl optionally containing a further one or two heteroatoms selected from N, O and S;
wherein said alkyl, cycloalkyl, alkoxy, aryl and heterocyclyl groups being optionally substituted by one or more atoms or groups independently selected from halo, OH, oxo, CF 3 , CN, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkoxy, —(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkylene-OH, —NR 11 R 12 , —(C 1 -C 6 )alkylene-NR 11 R 12 , aryl and 3 to 10-membered heterocyclyl; or
a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients,
with the proviso that when R 1 and R 2 are H, and Z and R 5 are absent, then
(a)R 4 is not methyl when Y—R 3 is ethyl; and
(b)R 4 is not H or methyl when Y—R 3 is methyl.
21. A pharmaceutical composition according to claim 20 , further comprising one or more additional therapeutic agents.
22. A pharmaceutical composition according to claim 21 , wherein said additional therapeutic agent is selected from inhibitors of HCV NS3A protein, HCV NS5A protein, HCV NS4B protein, HCV polymerase, HCV metalloprotease, HCV serine protease, HCV helicase and p7 protein.